Terms: = Prostate cancer AND PTEN, MMAC1, 5728, MGC11227, PTEN1, MHAM, P60484, BZS, ENSG00000171862 AND Staging
8 results:
1. The Brazilian national prospective active surveillance (AS) cohort of patients with low-risk prostate cancer in the public health system: vigiaSUS study protocol.
Basso J; de Lima JB; Bessel M; Tobar Leitão SA; Machado Baptista T; Roithmann S; Franco Carvalhal E; da Silva Schmitt C; Morzoletto Pedrollo I; Schuch A; Atalibio Hartmann A; Neubarth Estivallet CL; Behrend Silva Ribeiro G; Zordan RA; Isaacsson Velho P
BMC Urol; 2023 Dec; 23(1):208. PubMed ID: 38082337
[TBL] [Abstract] [Full Text] [Related]
2. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical prostatectomy for High-risk prostate cancer.
Devos G; Tosco L; Baldewijns M; Gevaert T; Goffin K; Petit V; Mai C; Laenen A; Raskin Y; Van Haute C; Goeman L; De Meerleer G; Berghen C; Devlies W; Claessens F; Van Poppel H; Everaerts W; Joniau S
Eur Urol; 2023 Jun; 83(6):508-518. PubMed ID: 36167599
[TBL] [Abstract] [Full Text] [Related]
3. Correlation between radiological and biological features and clinical outcomes in early prostate cancer: an exploratory subgroup analysis.
Corrao G; Marvaso G; Zaffaroni M; Volpe S; Augugliaro M; Fodor CI; Zerini D; Vingiani A; Mistretta FA; Luzzago S; Alessi S; Pricolo P; Musi G; De Cobelli O; Renne G; Manzoni M; Petralia G; Orecchia R; Jereczek-Fossa BA
Neoplasma; 2022 Mar; 69(2):404-411. PubMed ID: 35014537
[TBL] [Abstract] [Full Text] [Related]
4. Clinical Evaluation of FOXO1 as a Tumor Suppressor in prostate cancer.
Yang N; Wu J; Zhang T; Yang F; Shao J; He C; Qin L
Comput Math Methods Med; 2021; 2021():8773423. PubMed ID: 34552661
[TBL] [Abstract] [Full Text] [Related]
5. Evaluation of Intense Androgen Deprivation Before prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
McKay RR; Ye H; Xie W; Lis R; Calagua C; Zhang Z; Trinh QD; Chang SL; Harshman LC; Ross AE; Pienta KJ; Lin DW; Ellis WJ; Montgomery B; Chang P; Wagner AA; Bubley GJ; Kibel AS; Taplin ME
J Clin Oncol; 2019 Apr; 37(11):923-931. PubMed ID: 30811282
[TBL] [Abstract] [Full Text] [Related]
6. Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations.
Egevad L; Delahunt B; Kristiansen G; Samaratunga H; Varma M
Pathology; 2018 Jan; 50(1):60-73. PubMed ID: 29199015
[TBL] [Abstract] [Full Text] [Related]
7. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer.
Ishkanian AS; Zafarana G; Thoms J; Bristow RG
Acta Oncol; 2010 Oct; 49(7):888-94. PubMed ID: 20590366
[TBL] [Abstract] [Full Text] [Related]
8. MMAC/pten tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer.
Koul D; Shen R; Garyali A; Ke LD; Liu TJ; Yung WK
Int J Oncol; 2002 Sep; 21(3):469-75. PubMed ID: 12168088
[TBL] [Abstract] [Full Text] [Related]
